Literature DB >> 22391526

Proveblue (methylene blue) as an antimalarial agent: in vitro synergy with dihydroartemisinin and atorvastatin.

Jérôme Dormoi, Aurélie Pascual, Sébastien Briolant, Rémy Amalvict, Serge Charras, Eric Baret, Emilie Huyghues des Etages, Michel Feraud, Bruno Pradines.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22391526      PMCID： PMC3370790          DOI： 10.1128/AAC.06073-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  15 in total

1.  Synergy of mefloquine activity with atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the pfmdr1 gene.

Authors:  Nathalie Wurtz; Sébastien Briolant; Marine Gil; Véronique Parquet; Maud Henry; Eric Baret; Rémy Amalvict; Lionel Almeras; Christophe Rogier; Bruno Pradines
Journal:  J Antimicrob Chemother       Date:  2010-05-25       Impact factor: 5.790

2.  Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum.

Authors:  Bruno Pradines; Marylin Torrentino-Madamet; Albin Fontaine; Maud Henry; Eric Baret; Joel Mosnier; Sébastien Briolant; Thierry Fusai; Christophe Rogier
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191

3.  Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin.

Authors:  Hélène Savini; Jean Baptiste Souraud; Sébastien Briolant; Eric Baret; Rémy Amalvict; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191

4.  In vitro assessment of methylene blue on chloroquine-sensitive and -resistant Plasmodium falciparum strains reveals synergistic action with artemisinins.

Authors:  Monique Akoachere; Kathrin Buchholz; Elisabeth Fischer; Jürgen Burhenne; Walter E Haefeli; R Heiner Schirmer; Katja Becker
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

5.  Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.

Authors:  Sébastien Briolant; Maud Henry; Claude Oeuvray; Rémy Amalvict; Eric Baret; Eric Didillon; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

6.  Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum.

Authors:  Véronique Parquet; Maud Henry; Nathalie Wurtz; Jerome Dormoi; Sébastien Briolant; Marine Gil; Eric Baret; Rémy Amalvict; Christophe Rogier; Bruno Pradines
Journal:  Malar J       Date:  2010-05-25       Impact factor: 2.979

7.  Dihydroethanoanthracene derivatives reverse in vitro quinoline resistance in Plasmodium falciparum malaria.

Authors:  Maud Henry; Sandrine Alibert; Meili Baragatti; Joel Mosnier; Eric Baret; Rémy Amalvict; Eric Legrand; Thierry Fusai; Jacques Barbe; Christophe Rogier; Jean-Marie Pagès; Bruno Pradines
Journal:  Med Chem       Date:  2008-09       Impact factor: 2.745

8.  Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.

Authors:  Véronique Parquet; Sébastien Briolant; Marylin Torrentino-Madamet; Maud Henry; Lionel Almeras; Rémy Amalvict; Eric Baret; Thierry Fusaï; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

9.  Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial.

Authors:  Boubacar Coulibaly; Augustin Zoungrana; Frank P Mockenhaupt; R Heiner Schirmer; Christina Klose; Ulrich Mansmann; Peter E Meissner; Olaf Müller
Journal:  PLoS One       Date:  2009-05-05       Impact factor: 3.240

10.  Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.

Authors:  Augustin Zoungrana; Boubacar Coulibaly; Ali Sié; Ingeborg Walter-Sack; Frank P Mockenhaupt; Bocar Kouyaté; R Heiner Schirmer; Christina Klose; Ulrich Mansmann; Peter Meissner; Olaf Müller
Journal:  PLoS One       Date:  2008-02-20       Impact factor: 3.240
View more
  15 in total

1.  Dose responses of proveblue methylene blue in an experimental murine cerebral malaria model.

Authors:  Jérome Dormoi; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2013-05-13       Impact factor: 5.191

2.  Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax.

Authors:  Grennady Wirjanata; Boni F Sebayang; Ferryanto Chalfein; Irene Handayuni; Leily Trianty; Enny Kenangalem; Rintis Noviyanti; Brice Campo; Jeanne Rini Poespoprodjo; Jörg J Möhrle; Ric N Price; Jutta Marfurt
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

Review 3.  New insight-guided approaches to detect, cure, prevent and eliminate malaria.

Authors:  Sushil Kumar; Renu Kumari; Richa Pandey
Journal:  Protoplasma       Date:  2014-10-17       Impact factor: 3.356

4.  Arteether resistance reversal by ketoconazole/fluconazole in rodent malaria parasite Plasmodium vinckei.

Authors:  Ramesh Chandra; S K Puri
Journal:  Parasitol Res       Date:  2015-01-25       Impact factor: 2.289

5.  Efficacy of proveblue (methylene blue) in an experimental cerebral malaria murine model.

Authors:  Jérome Dormoi; Sébastien Briolant; Camille Desgrouas; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

6.  Pharmacokinetics and Ex Vivo Antimalarial Activity of Artesunate-Amodiaquine plus Methylene Blue in Healthy Volunteers.

Authors:  Chu Xuan Anh; Marina Chavchich; Geoffrey W Birrell; Karin Van Breda; Thomas Travers; Kerryn Rowcliffe; Anton R Lord; G Dennis Shanks; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

7.  Nucleoside-lipid-based nanocarriers for methylene blue delivery: potential application as anti-malarial drug.

Authors:  Koffi Kowouvi; Bruno Alies; Mathieu Gendrot; Alexandra Gaubert; Gaelle Vacher; Karen Gaudin; Joel Mosnier; Bruno Pradines; Philippe Barthelemy; Luc Grislain; Pascal Millet
Journal:  RSC Adv       Date:  2019-06-17       Impact factor: 4.036

8.  The Redox Cycler Plasmodione Is a Fast-Acting Antimalarial Lead Compound with Pronounced Activity against Sexual and Early Asexual Blood-Stage Parasites.

Authors:  Katharina Ehrhardt; Christiane Deregnaucourt; Alice-Anne Goetz; Tzvetomira Tzanova; Valentina Gallo; Paolo Arese; Bruno Pradines; Sophie H Adjalley; Denyse Bagrel; Stephanie Blandin; Michael Lanzer; Elisabeth Davioud-Charvet
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

9.  Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model.

Authors:  Jérome Dormoi; Sébastien Briolant; Camille Desgrouas; Bruno Pradines
Journal:  Malar J       Date:  2013-04-15       Impact factor: 2.979

10.  In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum.

Authors:  Jérome Dormoi; Hélène Savini; Rémy Amalvict; Eric Baret; Bruno Pradines
Journal:  Malar J       Date:  2014-05-25       Impact factor: 2.979
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.